Administration of aspartame in non‐insulin‐dependent diabetics

Stern, Sol B.; Bleicher, Sheldon J.; Flores, Angélica; Gombos, G.; Recitas, D.; Shu, Jun-Xiang

doi:10.1080/15287397609529444

Cited by 39 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, the effects of chronic ingestion of aspartame in diabetics should be further studied. Stern et al (4) have already reported that in 43 NIDDM patients daily administration of 1.8 g of aspartame in capsules for 90 days did not affect the fasting plasma glucose level and had no prominent side effects , although they did not check the insulin level. Therefore, our present observations combined with the report of Stern et al (4), suggest that NIDDM patients can use aspartame as a food additive without affecting their blood glucose level .…”

Section: Discussionmentioning

confidence: 99%

Effects of aspartame on diabetic rats and diabetic patients.

Shigeta

Yoshida

Nakai

et al. 1985

Journal of Nutritional Science and Vitaminology, J Nutr Sci Vit

View full text Add to dashboard Cite

SummaryThe effects of aspartame (L-aspartyl-L-phenylalanine methyl ester) on plasma glucose and insulin levels were investigated in diabetic rats and patients with non-insulin-dependent diabetes mellitus. The oral administration of 0.45mg aspartame per 100g body weight, which is equivalent to 150mg of glucose in sweetness, to streptozotocin-induced diabetic rats had no effect on the plasma glucose or insulin levels . Also, 225mg oral aspartame loading, which is equivalent to 75g of glucose in sweetness, to patients with non-insulin-dependent diabetes mellitus did not increase plasma glucose or insulin levels, although 75g of oral glucose loading increased plasma glucose and insulin levels in diabetic patients as expected. Aspartame ingestion for three days at a dose of 24-48 mg per day and the intake of snacks flavored with 240mg of aspartame also did not increase fasting plasma glucose levels. These results suggest that acute administration of aspartame has no influence on plasma glucose or insulin levels in diabetic rats and patients with non-insulin-dependent diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of aspartame on diabetic rats and diabetic patients.

Shigeta

Yoshida

Nakai

et al. 1985

Journal of Nutritional Science and Vitaminology, J Nutr Sci Vit

View full text Add to dashboard Cite

show abstract

“…Of the few clinical studies involving diabetic subjects, observations have been limited to determination of the effects of aspartame loading on blood glucose, lipids, serum insulin, plasma glucagon, and glycosylated hemoglobin concentrations (4)(5)(6)(7)(8).…”

mentioning

confidence: 99%

Aspartame Metabolism in Normal Adults, Phenylketonuric Heterozygotes, and Diabetic Subjects

Filer

Stegink

1989

Diabetes Care

View full text Add to dashboard Cite

This study reviews clinical studies testing the effects of various doses of aspartame on blood levels of phenylalanine, aspartate, and methanol in normal subjects and known phenylketonuric heterozygotes. The effect of aspartame on the phenylalanine-to-large neutral amino acid ratio under various feeding situations is shown. The clinical studies of aspartame in diabetic subjects are limited to observations of its effects on blood levels of glucose, lipids, insulin, and glucagon. These studies clearly demonstrate the safety of this high-intensity sweetener for use by humans. Diabetes Care 12:67-74, 1989 I n the United States the prevalence of diabetes, both insulin dependent (IDDM) and non-insulin dependent (NIDDM), involves 2.7% of women and 2.0% of men (1). In 1976, it was projected that the incidence of diabetes was increasing at a rate of 6%/yr (2). The association of NIDDM with the degree and duration of obesity suggests one reason why high-intensity sweeteners, nutritive and nonnutritive, may be a component of foods eaten by diabetic individuals. The natural interest of humans in the sweet taste modality provides another rationale for incorporation of high-intensity sweeteners into the diet of diabetic individuals. Currently, the most widely consumed high-intensity sweetener is aspartame, a dipeptide methyl ester (L-aspartyl-L-phenylalanine methyl ester).On the basis of total pounds of aspartame sold to food and beverage processors, it has been estimated that as- Daily intake can be calculated and amounts to 104 mg/day or 1.5 mg/kg body wt for a 70-kg individual. Aspartame is rarely consumed alone but is usually ingested in conjunction with varying proportions of carbohydrate, protein, and fat. Unless a person drinks an aspartame-sweetened beverage, carbonated or still, as a refreshment, the intake usually involves other foods. Aspartame-containing carbonated soft drinks provide 150-200 mg of aspartame per serving (12 oz or 360 ml). Noncarbonated beverages usually contain 140 mg per serving (8 oz or 240 ml). For the average 70-kg adult or 20-kg 4-yr-old, aspartame intake under these amounts would approximate 3-10 mg/kg body wt. The Market Research Corporation of America (MRCA) has projected the 99th percentile of daily intake of aspartame at 34 mg/kg body wt (3). Accordingly, the clinical studies highlighted in this review bracket aspartame intakes that range from 4 to 200 mg/kg body wt. These studies largely represent single-bolus doses of aspartame given to normal adult subjects, known adult phenylketonuric (PKU) heterozygotes, or normal 1-yr-olds. Aspartame was administered in orange juice, in a noncarbonated beverage, as part of a hamburger and milk shake meal, or in a beverage ingested at repeated intervals. Aspartame doses >50 mg/kg body wt were considered to represent abuse doses; i.e., 100-200 mg/kg body wt. Based on the relative sweetness of aspartame to sucrose, abuse intakes of this magnitude represent an acute intake of sweetness equivalent to 3-6 Ib of sucrose. Participants in the latter clinica...

show abstract

“…Few intervention studies have evaluated the effects of chronic LCS consumption on outcomes other than body weight [29, 48, 49, 66, 67]. Examples are clinical trials reporting on glycemia, in which no differences were observed following 6 weeks [49] or 90 days [66] treatment with aspartame compared to sucrose among adults with type 2 diabetes.…”

Section: Methodological Considerationsmentioning

confidence: 99%

“…Examples are clinical trials reporting on glycemia, in which no differences were observed following 6 weeks [49] or 90 days [66] treatment with aspartame compared to sucrose among adults with type 2 diabetes. Similar findings were reported with saccharin [48] and rebaudioside A [46].…”

Section: Methodological Considerationsmentioning

confidence: 99%

Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research

Sylvetsky

Blau

Rother

2016

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Consumption of foods, beverages, and packets containing low-calorie sweeteners (LCS) has increased markedly across gender, age, race/ethnicity, weight status, and socioeconomic subgroups. However, well-controlled intervention studies rigorously evaluating the health effects of LCS in humans are limited. One of the key questions is whether LCS are indeed a beneficial strategy for weight management and prevention of obesity. The current review discusses several methodological considerations in the design and interpretation of these studies. Specifically, we focus on the selection of study participants, inclusion of an appropriate control, importance of considering habitual LCS exposure, selection of specific LCS, dose and route of LCS administration, choice of study outcomes, and the context and generalizability of the study findings. These critical considerations will guide the design of future studies and thus assist in understanding the health effects of LCS.

show abstract

Administration of aspartame in non‐insulin‐dependent diabetics

Cited by 39 publications

References 0 publications

Effects of aspartame on diabetic rats and diabetic patients.

Effects of aspartame on diabetic rats and diabetic patients.

Aspartame Metabolism in Normal Adults, Phenylketonuric Heterozygotes, and Diabetic Subjects

Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research

Contact Info

Product

Resources

About